```json
{
"content": [
{
"type": "paragraph",
"content": "The ICAD (Intracranial Atherosclerotic Disease) Pathology market focuses on diagnostic solutions and therapeutic interventions for strokes caused by atherosclerosis in cerebral arteries. As a critical subset of cerebrovascular disease, ICAD represents a growing burden globally, particularly in Asia-Pacific and Africa, where underdiagnosed cases and rising comorbidities drive demand for advanced pathology tools. The ICAD Pathology market size reached $1.5 billion in 2025, reflecting robust growth outlook fueled by aging populations, rising stroke prevalence, and advancements in non-invasive imaging technologies. By 2033, the market is projected to expand at a CAGR of 7.2%, with market forecast models highlighting untapped potential in emerging economies."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Diagnostic Imaging", "Therapeutics", "Research & Development"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[1200, 1260, 1323, 1389, 1458, 1530, 1605, 1682, 1762, 1845, 1931, 2020, 2112], // Diagnostic Imaging
[800, 840, 882, 926, 972, 1020, 1071, 1125, 1181, 1240, 1302, 1366, 1433], // Therapeutics
[400, 420, 441, 463, 486, 510, 535, 561, 587, 615, 644, 675, 708] // R&D
]
}
},
{
"type": "paragraph",
"content": "The ICAD Pathology market is shaped by industry expansion in diagnostics, particularly AI-integrated imaging for early detection, and regulatory tailwinds promoting innovation in stroke care. Two pivotal forces driving growth include the shift toward minimally invasive therapies (e.g., balloon angioplasty) and the global push for standardized ICAD management protocols. North America remains the largest region due to high healthcare spending and established R&D ecosystems, while Asia-Pacific is the fastest-growing region, driven by rising awareness and improving diagnostic infrastructure. Strategic collaborations among diagnostic firms and pharmaceutical players are intensifying competitive dynamics, positioning the market for transformative growth by 2033."
}
]
}
```
